Global Oncogene-Targeted Drugs Supply, Demand and Key Producers, 2026-2032
The global Oncogene-Targeted Drugs market size is expected to reach $ 109166 million by 2032, rising at a market growth of 7.3% CAGR during the forecast period (2026-2032).
Oncogene-Targeted Drugs are antineoplastic medicines designed to act on oncogenic driver alterations and their encoded proteins, receptors, or downstream signaling pathways that play a critical role in tumor initiation, maintenance, and progression. They include small-molecule targeted agents and biologic products; the former are commonly formulated as tablets, capsules, or injectables, whereas the latter are typically injectable monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates. Their composition generally consists of an active pharmaceutical ingredient, excipients, and a suitable dosage-form system, and some products are used together with companion diagnostics. By selectively inhibiting abnormalities involving EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 and related drivers, these drugs block signaling required for cancer-cell proliferation, survival, angiogenesis, or metastasis, thereby improving therapeutic precision and reducing nonselective damage to normal tissues. They are widely used in molecularly defined solid tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and melanoma, as well as selected hematologic malignancies.
The industry position of Oncogene-Targeted Drugs is evolving from a specialized category within oncology therapeutics into a core value node of the precision medicine ecosystem. The primary opportunity comes from the ongoing shift in cancer care from tumor-type-based treatment to molecularly stratified treatment. An increasing number of clinical decisions are now built around the identification of driver alterations such as EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, and HER2, which means these drugs are no longer merely therapeutic end products. Instead, they are becoming part of a high-barrier solution set that integrates genomic testing, companion diagnostics, data interpretation, patient stratification, and real-world evidence. The NCI defines targeted therapy as treatment directed at specific changes that help cancer cells grow, spread, and survive, while the FDA recognizes companion diagnostics as essential to the clinical use of multiple oncology targeted therapies. This gives the segment value far beyond product revenue alone, extending into precision-use efficiency, pathway optimization, and stronger health-economic justification. For companies, the most attractive opportunity lies not in a single asset, but in building platform-based portfolios around advantaged targets, resistance management, combination regimens, and global registration strategies. For investors, the long-term appeal of this market lies in its unique combination of innovation intensity, clinically testable value, and commercial scalability. For policymakers, it represents a strategic lever for upgrading advanced biopharma, molecular diagnostics, and standardized oncology management.
At the same time, this market is not expanding in a linear manner. It is a classic high-R&D, high-regulation, high-competition arena where challenges and risks remain substantial. Commercial success is highly dependent on target validity and accurate patient selection; if the truly addressable patient pool proves smaller than expected, or if companion diagnostic penetration lags, market uptake can be materially constrained. Resistance is another structural challenge: early efficacy rarely guarantees durable positioning, and companies must continuously invest in next-generation molecules, combination strategies, and indication expansion or risk being displaced by new mechanisms. The barriers are not confined to discovery either; they extend across CMC, GMP, multi-region regulatory approval, pharmacovigilance, supply resilience, and reimbursement negotiations. This is especially relevant as more complex molecular modalities such as monoclonal antibodies, bispecifics, and ADCs expand within oncology. In this environment, manufacturing consistency, quality control, and global commercial delivery capability are becoming decisive competitive variables. More importantly, as biomarker-driven development becomes an industry norm, competition is shifting from a race to launch toward a race to build evidence loops, clinical consensus, and access advantages. Companies lacking integrated clinical development capability, diagnostic partnership depth, and international market access expertise will find it increasingly difficult to sustain leadership in high-value niches.
On the demand side, future growth is likely to be driven more by structural upgrading than by volume expansion alone. Hospitals and clinicians increasingly expect these therapies not only to improve response rates, but also to support earlier intervention, more precise stratification, longer survival benefit, and more manageable safety profiles. This is pushing usage from late-stage salvage settings toward adjuvant, neoadjuvant, perioperative, and maintenance settings. At the same time, payers and health systems are moving beyond innovation labels and focusing more closely on real-world outcomes, post-resistance treatment pathways, testing accessibility, and total cost of care. As a result, products that are tightly linked with companion diagnostics, supported by clear patient-selection logic, and embedded into standardized treatment pathways will be better positioned to sustain demand. The downstream customer landscape is also broadening. In addition to major cancer centers, regional hospitals, specialist networks, molecular pathology laboratories, and precision medicine service platforms are playing a larger role, prompting drug makers to move beyond conventional academic promotion toward integrated go-to-market models built around therapeutics, diagnostics, education, and patient management. Overall, demand fundamentals for oncogene-targeted drugs are expected to remain resilient, but the next phase of market deepening will be driven not by conceptual innovation alone, but by system-level solutions capable of balancing molecular diagnostics, therapeutic benefit, accessibility, and commercial reproducibility.
This report studies the global Oncogene-Targeted Drugs demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oncogene-Targeted Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oncogene-Targeted Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oncogene-Targeted Drugs total market, 2021-2032, (USD Million)
Global Oncogene-Targeted Drugs total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Oncogene-Targeted Drugs total market, key domestic companies, and share, (USD Million)
Global Oncogene-Targeted Drugs revenue by player, revenue and market share 2021-2026, (USD Million)
Global Oncogene-Targeted Drugs total market by Type, CAGR, 2021-2032, (USD Million)
Global Oncogene-Targeted Drugs total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Oncogene-Targeted Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Roche, Pfizer, AstraZeneca, Eli Lilly, Novartis, Bristol Myers Squibb, Bayer, Takeda, Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Oncogene-Targeted Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Oncogene-Targeted Drugs Market, By Region:
1. How big is the global Oncogene-Targeted Drugs market?
2. What is the demand of the global Oncogene-Targeted Drugs market?
3. What is the year over year growth of the global Oncogene-Targeted Drugs market?
4. What is the total value of the global Oncogene-Targeted Drugs market?
5. Who are the Major Players in the global Oncogene-Targeted Drugs market?
6. What are the growth factors driving the market demand?
Oncogene-Targeted Drugs are antineoplastic medicines designed to act on oncogenic driver alterations and their encoded proteins, receptors, or downstream signaling pathways that play a critical role in tumor initiation, maintenance, and progression. They include small-molecule targeted agents and biologic products; the former are commonly formulated as tablets, capsules, or injectables, whereas the latter are typically injectable monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates. Their composition generally consists of an active pharmaceutical ingredient, excipients, and a suitable dosage-form system, and some products are used together with companion diagnostics. By selectively inhibiting abnormalities involving EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 and related drivers, these drugs block signaling required for cancer-cell proliferation, survival, angiogenesis, or metastasis, thereby improving therapeutic precision and reducing nonselective damage to normal tissues. They are widely used in molecularly defined solid tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and melanoma, as well as selected hematologic malignancies.
The industry position of Oncogene-Targeted Drugs is evolving from a specialized category within oncology therapeutics into a core value node of the precision medicine ecosystem. The primary opportunity comes from the ongoing shift in cancer care from tumor-type-based treatment to molecularly stratified treatment. An increasing number of clinical decisions are now built around the identification of driver alterations such as EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, and HER2, which means these drugs are no longer merely therapeutic end products. Instead, they are becoming part of a high-barrier solution set that integrates genomic testing, companion diagnostics, data interpretation, patient stratification, and real-world evidence. The NCI defines targeted therapy as treatment directed at specific changes that help cancer cells grow, spread, and survive, while the FDA recognizes companion diagnostics as essential to the clinical use of multiple oncology targeted therapies. This gives the segment value far beyond product revenue alone, extending into precision-use efficiency, pathway optimization, and stronger health-economic justification. For companies, the most attractive opportunity lies not in a single asset, but in building platform-based portfolios around advantaged targets, resistance management, combination regimens, and global registration strategies. For investors, the long-term appeal of this market lies in its unique combination of innovation intensity, clinically testable value, and commercial scalability. For policymakers, it represents a strategic lever for upgrading advanced biopharma, molecular diagnostics, and standardized oncology management.
At the same time, this market is not expanding in a linear manner. It is a classic high-R&D, high-regulation, high-competition arena where challenges and risks remain substantial. Commercial success is highly dependent on target validity and accurate patient selection; if the truly addressable patient pool proves smaller than expected, or if companion diagnostic penetration lags, market uptake can be materially constrained. Resistance is another structural challenge: early efficacy rarely guarantees durable positioning, and companies must continuously invest in next-generation molecules, combination strategies, and indication expansion or risk being displaced by new mechanisms. The barriers are not confined to discovery either; they extend across CMC, GMP, multi-region regulatory approval, pharmacovigilance, supply resilience, and reimbursement negotiations. This is especially relevant as more complex molecular modalities such as monoclonal antibodies, bispecifics, and ADCs expand within oncology. In this environment, manufacturing consistency, quality control, and global commercial delivery capability are becoming decisive competitive variables. More importantly, as biomarker-driven development becomes an industry norm, competition is shifting from a race to launch toward a race to build evidence loops, clinical consensus, and access advantages. Companies lacking integrated clinical development capability, diagnostic partnership depth, and international market access expertise will find it increasingly difficult to sustain leadership in high-value niches.
On the demand side, future growth is likely to be driven more by structural upgrading than by volume expansion alone. Hospitals and clinicians increasingly expect these therapies not only to improve response rates, but also to support earlier intervention, more precise stratification, longer survival benefit, and more manageable safety profiles. This is pushing usage from late-stage salvage settings toward adjuvant, neoadjuvant, perioperative, and maintenance settings. At the same time, payers and health systems are moving beyond innovation labels and focusing more closely on real-world outcomes, post-resistance treatment pathways, testing accessibility, and total cost of care. As a result, products that are tightly linked with companion diagnostics, supported by clear patient-selection logic, and embedded into standardized treatment pathways will be better positioned to sustain demand. The downstream customer landscape is also broadening. In addition to major cancer centers, regional hospitals, specialist networks, molecular pathology laboratories, and precision medicine service platforms are playing a larger role, prompting drug makers to move beyond conventional academic promotion toward integrated go-to-market models built around therapeutics, diagnostics, education, and patient management. Overall, demand fundamentals for oncogene-targeted drugs are expected to remain resilient, but the next phase of market deepening will be driven not by conceptual innovation alone, but by system-level solutions capable of balancing molecular diagnostics, therapeutic benefit, accessibility, and commercial reproducibility.
This report studies the global Oncogene-Targeted Drugs demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oncogene-Targeted Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oncogene-Targeted Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oncogene-Targeted Drugs total market, 2021-2032, (USD Million)
Global Oncogene-Targeted Drugs total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Oncogene-Targeted Drugs total market, key domestic companies, and share, (USD Million)
Global Oncogene-Targeted Drugs revenue by player, revenue and market share 2021-2026, (USD Million)
Global Oncogene-Targeted Drugs total market by Type, CAGR, 2021-2032, (USD Million)
Global Oncogene-Targeted Drugs total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Oncogene-Targeted Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Roche, Pfizer, AstraZeneca, Eli Lilly, Novartis, Bristol Myers Squibb, Bayer, Takeda, Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Oncogene-Targeted Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Oncogene-Targeted Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Axitinib (Inlyta)
- Ponatinib (Iclusig)
- Imatinib (Gleevec)
- Sunitinib (Sutent)
- Pazopanib (Votrient)
- Dabrafenib (Tafinlar)
- Vandetanib (Caprelsa)
- Vemurafenib (Zelboraf)
- Cabozantinib (Cabometyx and Cometriq)
- Sorafenib (Nexavar)
- Chemical Synthesis Product
- Semi-Synthetic Product
- Recombinant Expression Product
- Cell-Culture Derived Product
- Enzymatic Synthesis Product
- Oligonucleotide Solid-Phase Synthesis Product
- Conjugation Process Product
- Bottle Presentation
- Blister Presentation
- Vial Presentation
- Ampoule Presentation
- Prefilled Syringe Presentation
- Cartridge Presentation
- Infusion Bag Presentation
- Clinic
- Hospital
- Others
- Johnson & Johnson
- Roche
- Pfizer
- AstraZeneca
- Eli Lilly
- Novartis
- Bristol Myers Squibb
- Bayer
- Takeda
- Amgen
- Boehringer Ingelheim
- Daiichi Sankyo
- Hengrui
- Hansoh
- Betta
1. How big is the global Oncogene-Targeted Drugs market?
2. What is the demand of the global Oncogene-Targeted Drugs market?
3. What is the year over year growth of the global Oncogene-Targeted Drugs market?
4. What is the total value of the global Oncogene-Targeted Drugs market?
5. Who are the Major Players in the global Oncogene-Targeted Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Oncogene-Targeted Drugs Introduction
1.2 World Oncogene-Targeted Drugs Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Oncogene-Targeted Drugs Total Market by Region (by Headquarter Location)
1.3.1 World Oncogene-Targeted Drugs Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.3 China Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.4 Europe Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.5 Japan Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.6 South Korea Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.7 ASEAN Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.8 India Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oncogene-Targeted Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.2 World Oncogene-Targeted Drugs Consumption Value by Region
2.2.1 World Oncogene-Targeted Drugs Consumption Value by Region (2021-2026)
2.2.2 World Oncogene-Targeted Drugs Consumption Value Forecast by Region (2027-2032)
2.3 United States Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.4 China Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.5 Europe Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.6 Japan Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.7 South Korea Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.8 ASEAN Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.9 India Oncogene-Targeted Drugs Consumption Value (2021-2032)
3 WORLD ONCOGENE-TARGETED DRUGS COMPANIES COMPETITIVE ANALYSIS
3.1 World Oncogene-Targeted Drugs Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oncogene-Targeted Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oncogene-Targeted Drugs in 2025
3.2.3 Global Concentration Ratios (CR8) for Oncogene-Targeted Drugs in 2025
3.3 Oncogene-Targeted Drugs Company Evaluation Quadrant
3.4 Oncogene-Targeted Drugs Market: Overall Company Footprint Analysis
3.4.1 Oncogene-Targeted Drugs Market: Region Footprint
3.4.2 Oncogene-Targeted Drugs Market: Company Product Type Footprint
3.4.3 Oncogene-Targeted Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oncogene-Targeted Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oncogene-Targeted Drugs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Oncogene-Targeted Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Oncogene-Targeted Drugs Consumption Value Comparison
4.2.1 United States VS China: Oncogene-Targeted Drugs Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Oncogene-Targeted Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Oncogene-Targeted Drugs Companies and Market Share, 2021-2026
4.3.1 United States Based Oncogene-Targeted Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026)
4.4 China Based Companies Oncogene-Targeted Drugs Revenue and Market Share, 2021-2026
4.4.1 China Based Oncogene-Targeted Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026)
4.5 Rest of World Based Oncogene-Targeted Drugs Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Oncogene-Targeted Drugs Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Oncogene-Targeted Drugs Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Oncogene-Targeted Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Axitinib (Inlyta)
5.2.2 Ponatinib (Iclusig)
5.2.3 Imatinib (Gleevec)
5.2.4 Sunitinib (Sutent)
5.2.5 Pazopanib (Votrient)
5.2.6 Dabrafenib (Tafinlar)
5.2.7 Vandetanib (Caprelsa)
5.2.8 Vemurafenib (Zelboraf)
5.2.9 Cabozantinib (Cabometyx and Cometriq)
5.3 Market Segment by Type
5.3.1 World Oncogene-Targeted Drugs Market Size by Type (2021-2026)
5.3.2 World Oncogene-Targeted Drugs Market Size by Type (2027-2032)
5.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY MANUFACTURING PROCESS
6.1 World Oncogene-Targeted Drugs Market Size Overview by Manufacturing Process: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Manufacturing Process
6.2.1 Chemical Synthesis Product
6.2.2 Semi-Synthetic Product
6.2.3 Recombinant Expression Product
6.2.4 Cell-Culture Derived Product
6.2.5 Enzymatic Synthesis Product
6.2.6 Oligonucleotide Solid-Phase Synthesis Product
6.2.7 Conjugation Process Product
6.3 Market Segment by Manufacturing Process
6.3.1 World Oncogene-Targeted Drugs Market Size by Manufacturing Process (2021-2026)
6.3.2 World Oncogene-Targeted Drugs Market Size by Manufacturing Process (2027-2032)
6.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2027-2032)
7 MARKET ANALYSIS BY DRUG-DELIVERY PRESENTATION
7.1 World Oncogene-Targeted Drugs Market Size Overview by Drug-Delivery Presentation: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Drug-Delivery Presentation
7.2.1 Bottle Presentation
7.2.2 Blister Presentation
7.2.3 Vial Presentation
7.2.4 Ampoule Presentation
7.2.5 Prefilled Syringe Presentation
7.2.6 Cartridge Presentation
7.2.7 Infusion Bag Presentation
7.3 Market Segment by Drug-Delivery Presentation
7.3.1 World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2021-2026)
7.3.2 World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2027-2032)
7.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Oncogene-Targeted Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Clinic
8.2.2 Hospital
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Oncogene-Targeted Drugs Market Size by Application (2021-2026)
8.3.2 World Oncogene-Targeted Drugs Market Size by Application (2027-2032)
8.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Johnson & Johnson
9.1.1 Johnson & Johnson Details
9.1.2 Johnson & Johnson Major Business
9.1.3 Johnson & Johnson Oncogene-Targeted Drugs Product and Services
9.1.4 Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Johnson & Johnson Recent Developments/Updates
9.1.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Oncogene-Targeted Drugs Product and Services
9.2.4 Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 Pfizer
9.3.1 Pfizer Details
9.3.2 Pfizer Major Business
9.3.3 Pfizer Oncogene-Targeted Drugs Product and Services
9.3.4 Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Pfizer Recent Developments/Updates
9.3.6 Pfizer Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca Oncogene-Targeted Drugs Product and Services
9.4.4 AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Eli Lilly
9.5.1 Eli Lilly Details
9.5.2 Eli Lilly Major Business
9.5.3 Eli Lilly Oncogene-Targeted Drugs Product and Services
9.5.4 Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Eli Lilly Recent Developments/Updates
9.5.6 Eli Lilly Competitive Strengths & Weaknesses
9.6 Novartis
9.6.1 Novartis Details
9.6.2 Novartis Major Business
9.6.3 Novartis Oncogene-Targeted Drugs Product and Services
9.6.4 Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Novartis Recent Developments/Updates
9.6.6 Novartis Competitive Strengths & Weaknesses
9.7 Bristol Myers Squibb
9.7.1 Bristol Myers Squibb Details
9.7.2 Bristol Myers Squibb Major Business
9.7.3 Bristol Myers Squibb Oncogene-Targeted Drugs Product and Services
9.7.4 Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Bristol Myers Squibb Recent Developments/Updates
9.7.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.8 Bayer
9.8.1 Bayer Details
9.8.2 Bayer Major Business
9.8.3 Bayer Oncogene-Targeted Drugs Product and Services
9.8.4 Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Bayer Recent Developments/Updates
9.8.6 Bayer Competitive Strengths & Weaknesses
9.9 Takeda
9.9.1 Takeda Details
9.9.2 Takeda Major Business
9.9.3 Takeda Oncogene-Targeted Drugs Product and Services
9.9.4 Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Takeda Recent Developments/Updates
9.9.6 Takeda Competitive Strengths & Weaknesses
9.10 Amgen
9.10.1 Amgen Details
9.10.2 Amgen Major Business
9.10.3 Amgen Oncogene-Targeted Drugs Product and Services
9.10.4 Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Amgen Recent Developments/Updates
9.10.6 Amgen Competitive Strengths & Weaknesses
9.11 Boehringer Ingelheim
9.11.1 Boehringer Ingelheim Details
9.11.2 Boehringer Ingelheim Major Business
9.11.3 Boehringer Ingelheim Oncogene-Targeted Drugs Product and Services
9.11.4 Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Boehringer Ingelheim Recent Developments/Updates
9.11.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.12 Daiichi Sankyo
9.12.1 Daiichi Sankyo Details
9.12.2 Daiichi Sankyo Major Business
9.12.3 Daiichi Sankyo Oncogene-Targeted Drugs Product and Services
9.12.4 Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Daiichi Sankyo Recent Developments/Updates
9.12.6 Daiichi Sankyo Competitive Strengths & Weaknesses
9.13 Hengrui
9.13.1 Hengrui Details
9.13.2 Hengrui Major Business
9.13.3 Hengrui Oncogene-Targeted Drugs Product and Services
9.13.4 Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Hengrui Recent Developments/Updates
9.13.6 Hengrui Competitive Strengths & Weaknesses
9.14 Hansoh
9.14.1 Hansoh Details
9.14.2 Hansoh Major Business
9.14.3 Hansoh Oncogene-Targeted Drugs Product and Services
9.14.4 Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Hansoh Recent Developments/Updates
9.14.6 Hansoh Competitive Strengths & Weaknesses
9.15 Betta
9.15.1 Betta Details
9.15.2 Betta Major Business
9.15.3 Betta Oncogene-Targeted Drugs Product and Services
9.15.4 Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Betta Recent Developments/Updates
9.15.6 Betta Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Oncogene-Targeted Drugs Industry Chain
10.2 Oncogene-Targeted Drugs Upstream Analysis
10.3 Oncogene-Targeted Drugs Midstream Analysis
10.4 Oncogene-Targeted Drugs Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Oncogene-Targeted Drugs Introduction
1.2 World Oncogene-Targeted Drugs Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Oncogene-Targeted Drugs Total Market by Region (by Headquarter Location)
1.3.1 World Oncogene-Targeted Drugs Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.3 China Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.4 Europe Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.5 Japan Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.6 South Korea Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.7 ASEAN Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.3.8 India Based Company Oncogene-Targeted Drugs Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oncogene-Targeted Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.2 World Oncogene-Targeted Drugs Consumption Value by Region
2.2.1 World Oncogene-Targeted Drugs Consumption Value by Region (2021-2026)
2.2.2 World Oncogene-Targeted Drugs Consumption Value Forecast by Region (2027-2032)
2.3 United States Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.4 China Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.5 Europe Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.6 Japan Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.7 South Korea Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.8 ASEAN Oncogene-Targeted Drugs Consumption Value (2021-2032)
2.9 India Oncogene-Targeted Drugs Consumption Value (2021-2032)
3 WORLD ONCOGENE-TARGETED DRUGS COMPANIES COMPETITIVE ANALYSIS
3.1 World Oncogene-Targeted Drugs Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oncogene-Targeted Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oncogene-Targeted Drugs in 2025
3.2.3 Global Concentration Ratios (CR8) for Oncogene-Targeted Drugs in 2025
3.3 Oncogene-Targeted Drugs Company Evaluation Quadrant
3.4 Oncogene-Targeted Drugs Market: Overall Company Footprint Analysis
3.4.1 Oncogene-Targeted Drugs Market: Region Footprint
3.4.2 Oncogene-Targeted Drugs Market: Company Product Type Footprint
3.4.3 Oncogene-Targeted Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oncogene-Targeted Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oncogene-Targeted Drugs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Oncogene-Targeted Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Oncogene-Targeted Drugs Consumption Value Comparison
4.2.1 United States VS China: Oncogene-Targeted Drugs Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Oncogene-Targeted Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Oncogene-Targeted Drugs Companies and Market Share, 2021-2026
4.3.1 United States Based Oncogene-Targeted Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026)
4.4 China Based Companies Oncogene-Targeted Drugs Revenue and Market Share, 2021-2026
4.4.1 China Based Oncogene-Targeted Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026)
4.5 Rest of World Based Oncogene-Targeted Drugs Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Oncogene-Targeted Drugs Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Oncogene-Targeted Drugs Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Oncogene-Targeted Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Axitinib (Inlyta)
5.2.2 Ponatinib (Iclusig)
5.2.3 Imatinib (Gleevec)
5.2.4 Sunitinib (Sutent)
5.2.5 Pazopanib (Votrient)
5.2.6 Dabrafenib (Tafinlar)
5.2.7 Vandetanib (Caprelsa)
5.2.8 Vemurafenib (Zelboraf)
5.2.9 Cabozantinib (Cabometyx and Cometriq)
5.3 Market Segment by Type
5.3.1 World Oncogene-Targeted Drugs Market Size by Type (2021-2026)
5.3.2 World Oncogene-Targeted Drugs Market Size by Type (2027-2032)
5.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY MANUFACTURING PROCESS
6.1 World Oncogene-Targeted Drugs Market Size Overview by Manufacturing Process: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Manufacturing Process
6.2.1 Chemical Synthesis Product
6.2.2 Semi-Synthetic Product
6.2.3 Recombinant Expression Product
6.2.4 Cell-Culture Derived Product
6.2.5 Enzymatic Synthesis Product
6.2.6 Oligonucleotide Solid-Phase Synthesis Product
6.2.7 Conjugation Process Product
6.3 Market Segment by Manufacturing Process
6.3.1 World Oncogene-Targeted Drugs Market Size by Manufacturing Process (2021-2026)
6.3.2 World Oncogene-Targeted Drugs Market Size by Manufacturing Process (2027-2032)
6.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2027-2032)
7 MARKET ANALYSIS BY DRUG-DELIVERY PRESENTATION
7.1 World Oncogene-Targeted Drugs Market Size Overview by Drug-Delivery Presentation: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Drug-Delivery Presentation
7.2.1 Bottle Presentation
7.2.2 Blister Presentation
7.2.3 Vial Presentation
7.2.4 Ampoule Presentation
7.2.5 Prefilled Syringe Presentation
7.2.6 Cartridge Presentation
7.2.7 Infusion Bag Presentation
7.3 Market Segment by Drug-Delivery Presentation
7.3.1 World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2021-2026)
7.3.2 World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2027-2032)
7.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Oncogene-Targeted Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Clinic
8.2.2 Hospital
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Oncogene-Targeted Drugs Market Size by Application (2021-2026)
8.3.2 World Oncogene-Targeted Drugs Market Size by Application (2027-2032)
8.3.3 World Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Johnson & Johnson
9.1.1 Johnson & Johnson Details
9.1.2 Johnson & Johnson Major Business
9.1.3 Johnson & Johnson Oncogene-Targeted Drugs Product and Services
9.1.4 Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Johnson & Johnson Recent Developments/Updates
9.1.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Oncogene-Targeted Drugs Product and Services
9.2.4 Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 Pfizer
9.3.1 Pfizer Details
9.3.2 Pfizer Major Business
9.3.3 Pfizer Oncogene-Targeted Drugs Product and Services
9.3.4 Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Pfizer Recent Developments/Updates
9.3.6 Pfizer Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca Oncogene-Targeted Drugs Product and Services
9.4.4 AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Eli Lilly
9.5.1 Eli Lilly Details
9.5.2 Eli Lilly Major Business
9.5.3 Eli Lilly Oncogene-Targeted Drugs Product and Services
9.5.4 Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Eli Lilly Recent Developments/Updates
9.5.6 Eli Lilly Competitive Strengths & Weaknesses
9.6 Novartis
9.6.1 Novartis Details
9.6.2 Novartis Major Business
9.6.3 Novartis Oncogene-Targeted Drugs Product and Services
9.6.4 Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Novartis Recent Developments/Updates
9.6.6 Novartis Competitive Strengths & Weaknesses
9.7 Bristol Myers Squibb
9.7.1 Bristol Myers Squibb Details
9.7.2 Bristol Myers Squibb Major Business
9.7.3 Bristol Myers Squibb Oncogene-Targeted Drugs Product and Services
9.7.4 Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Bristol Myers Squibb Recent Developments/Updates
9.7.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.8 Bayer
9.8.1 Bayer Details
9.8.2 Bayer Major Business
9.8.3 Bayer Oncogene-Targeted Drugs Product and Services
9.8.4 Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Bayer Recent Developments/Updates
9.8.6 Bayer Competitive Strengths & Weaknesses
9.9 Takeda
9.9.1 Takeda Details
9.9.2 Takeda Major Business
9.9.3 Takeda Oncogene-Targeted Drugs Product and Services
9.9.4 Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Takeda Recent Developments/Updates
9.9.6 Takeda Competitive Strengths & Weaknesses
9.10 Amgen
9.10.1 Amgen Details
9.10.2 Amgen Major Business
9.10.3 Amgen Oncogene-Targeted Drugs Product and Services
9.10.4 Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Amgen Recent Developments/Updates
9.10.6 Amgen Competitive Strengths & Weaknesses
9.11 Boehringer Ingelheim
9.11.1 Boehringer Ingelheim Details
9.11.2 Boehringer Ingelheim Major Business
9.11.3 Boehringer Ingelheim Oncogene-Targeted Drugs Product and Services
9.11.4 Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Boehringer Ingelheim Recent Developments/Updates
9.11.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.12 Daiichi Sankyo
9.12.1 Daiichi Sankyo Details
9.12.2 Daiichi Sankyo Major Business
9.12.3 Daiichi Sankyo Oncogene-Targeted Drugs Product and Services
9.12.4 Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Daiichi Sankyo Recent Developments/Updates
9.12.6 Daiichi Sankyo Competitive Strengths & Weaknesses
9.13 Hengrui
9.13.1 Hengrui Details
9.13.2 Hengrui Major Business
9.13.3 Hengrui Oncogene-Targeted Drugs Product and Services
9.13.4 Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Hengrui Recent Developments/Updates
9.13.6 Hengrui Competitive Strengths & Weaknesses
9.14 Hansoh
9.14.1 Hansoh Details
9.14.2 Hansoh Major Business
9.14.3 Hansoh Oncogene-Targeted Drugs Product and Services
9.14.4 Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Hansoh Recent Developments/Updates
9.14.6 Hansoh Competitive Strengths & Weaknesses
9.15 Betta
9.15.1 Betta Details
9.15.2 Betta Major Business
9.15.3 Betta Oncogene-Targeted Drugs Product and Services
9.15.4 Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Betta Recent Developments/Updates
9.15.6 Betta Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Oncogene-Targeted Drugs Industry Chain
10.2 Oncogene-Targeted Drugs Upstream Analysis
10.3 Oncogene-Targeted Drugs Midstream Analysis
10.4 Oncogene-Targeted Drugs Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Oncogene-Targeted Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Oncogene-Targeted Drugs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Oncogene-Targeted Drugs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Oncogene-Targeted Drugs Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Oncogene-Targeted Drugs Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oncogene-Targeted Drugs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Oncogene-Targeted Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Oncogene-Targeted Drugs Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Oncogene-Targeted Drugs Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Oncogene-Targeted Drugs Players in 2025
Table 12. World Oncogene-Targeted Drugs Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Oncogene-Targeted Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Oncogene-Targeted Drugs Players
Table 15. Oncogene-Targeted Drugs Market: Company Product Type Footprint
Table 16. Oncogene-Targeted Drugs Market: Company Product Application Footprint
Table 17. Oncogene-Targeted Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Oncogene-Targeted Drugs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Oncogene-Targeted Drugs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Oncogene-Targeted Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Oncogene-Targeted Drugs Revenue Market Share (2021-2026)
Table 23. China Based Oncogene-Targeted Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Oncogene-Targeted Drugs Revenue Market Share (2021-2026)
Table 26. Rest of World Based Oncogene-Targeted Drugs Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Oncogene-Targeted Drugs Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Oncogene-Targeted Drugs Revenue Market Share (2021-2026)
Table 29. World Oncogene-Targeted Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Oncogene-Targeted Drugs Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Oncogene-Targeted Drugs Market Size by Type (2027-2032) & (USD Million)
Table 32. World Oncogene-Targeted Drugs Market Size by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Table 33. World Oncogene-Targeted Drugs Market Size Value by Manufacturing Process (2021-2026) & (USD Million)
Table 34. World Oncogene-Targeted Drugs Market Size by Manufacturing Process (2027-2032) & (USD Million)
Table 35. World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Table 36. World Oncogene-Targeted Drugs Market Size Value by Drug-Delivery Presentation (2021-2026) & (USD Million)
Table 37. World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2027-2032) & (USD Million)
Table 38. World Oncogene-Targeted Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Oncogene-Targeted Drugs Market Size by Application (2021-2026) & (USD Million)
Table 40. World Oncogene-Targeted Drugs Market Size by Application (2027-2032) & (USD Million)
Table 41. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 42. Johnson & Johnson Major Business
Table 43. Johnson & Johnson Oncogene-Targeted Drugs Product and Services
Table 44. Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Johnson & Johnson Recent Developments/Updates
Table 46. Johnson & Johnson Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Oncogene-Targeted Drugs Product and Services
Table 50. Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. Pfizer Basic Information, Manufacturing Base and Competitors
Table 54. Pfizer Major Business
Table 55. Pfizer Oncogene-Targeted Drugs Product and Services
Table 56. Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Pfizer Recent Developments/Updates
Table 58. Pfizer Competitive Strengths & Weaknesses
Table 59. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca Major Business
Table 61. AstraZeneca Oncogene-Targeted Drugs Product and Services
Table 62. AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca Recent Developments/Updates
Table 64. AstraZeneca Competitive Strengths & Weaknesses
Table 65. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 66. Eli Lilly Major Business
Table 67. Eli Lilly Oncogene-Targeted Drugs Product and Services
Table 68. Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Eli Lilly Recent Developments/Updates
Table 70. Eli Lilly Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Manufacturing Base and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Oncogene-Targeted Drugs Product and Services
Table 74. Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 78. Bristol Myers Squibb Major Business
Table 79. Bristol Myers Squibb Oncogene-Targeted Drugs Product and Services
Table 80. Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Bristol Myers Squibb Recent Developments/Updates
Table 82. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 83. Bayer Basic Information, Manufacturing Base and Competitors
Table 84. Bayer Major Business
Table 85. Bayer Oncogene-Targeted Drugs Product and Services
Table 86. Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Bayer Recent Developments/Updates
Table 88. Bayer Competitive Strengths & Weaknesses
Table 89. Takeda Basic Information, Manufacturing Base and Competitors
Table 90. Takeda Major Business
Table 91. Takeda Oncogene-Targeted Drugs Product and Services
Table 92. Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Takeda Recent Developments/Updates
Table 94. Takeda Competitive Strengths & Weaknesses
Table 95. Amgen Basic Information, Manufacturing Base and Competitors
Table 96. Amgen Major Business
Table 97. Amgen Oncogene-Targeted Drugs Product and Services
Table 98. Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Amgen Recent Developments/Updates
Table 100. Amgen Competitive Strengths & Weaknesses
Table 101. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 102. Boehringer Ingelheim Major Business
Table 103. Boehringer Ingelheim Oncogene-Targeted Drugs Product and Services
Table 104. Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Boehringer Ingelheim Recent Developments/Updates
Table 106. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 107. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 108. Daiichi Sankyo Major Business
Table 109. Daiichi Sankyo Oncogene-Targeted Drugs Product and Services
Table 110. Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Daiichi Sankyo Recent Developments/Updates
Table 112. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 113. Hengrui Basic Information, Manufacturing Base and Competitors
Table 114. Hengrui Major Business
Table 115. Hengrui Oncogene-Targeted Drugs Product and Services
Table 116. Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Hengrui Recent Developments/Updates
Table 118. Hengrui Competitive Strengths & Weaknesses
Table 119. Hansoh Basic Information, Manufacturing Base and Competitors
Table 120. Hansoh Major Business
Table 121. Hansoh Oncogene-Targeted Drugs Product and Services
Table 122. Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Hansoh Recent Developments/Updates
Table 124. Hansoh Competitive Strengths & Weaknesses
Table 125. Betta Basic Information, Manufacturing Base and Competitors
Table 126. Betta Major Business
Table 127. Betta Oncogene-Targeted Drugs Product and Services
Table 128. Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Betta Recent Developments/Updates
Table 130. Betta Competitive Strengths & Weaknesses
Table 131. Global Key Players of Oncogene-Targeted Drugs Upstream (Raw Materials)
Table 132. Global Oncogene-Targeted Drugs Typical Customers
Table 1. World Oncogene-Targeted Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Oncogene-Targeted Drugs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Oncogene-Targeted Drugs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Oncogene-Targeted Drugs Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Oncogene-Targeted Drugs Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oncogene-Targeted Drugs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Oncogene-Targeted Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Oncogene-Targeted Drugs Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Oncogene-Targeted Drugs Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Oncogene-Targeted Drugs Players in 2025
Table 12. World Oncogene-Targeted Drugs Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Oncogene-Targeted Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Oncogene-Targeted Drugs Players
Table 15. Oncogene-Targeted Drugs Market: Company Product Type Footprint
Table 16. Oncogene-Targeted Drugs Market: Company Product Application Footprint
Table 17. Oncogene-Targeted Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Oncogene-Targeted Drugs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Oncogene-Targeted Drugs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Oncogene-Targeted Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Oncogene-Targeted Drugs Revenue Market Share (2021-2026)
Table 23. China Based Oncogene-Targeted Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oncogene-Targeted Drugs Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Oncogene-Targeted Drugs Revenue Market Share (2021-2026)
Table 26. Rest of World Based Oncogene-Targeted Drugs Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Oncogene-Targeted Drugs Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Oncogene-Targeted Drugs Revenue Market Share (2021-2026)
Table 29. World Oncogene-Targeted Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Oncogene-Targeted Drugs Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Oncogene-Targeted Drugs Market Size by Type (2027-2032) & (USD Million)
Table 32. World Oncogene-Targeted Drugs Market Size by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Table 33. World Oncogene-Targeted Drugs Market Size Value by Manufacturing Process (2021-2026) & (USD Million)
Table 34. World Oncogene-Targeted Drugs Market Size by Manufacturing Process (2027-2032) & (USD Million)
Table 35. World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Table 36. World Oncogene-Targeted Drugs Market Size Value by Drug-Delivery Presentation (2021-2026) & (USD Million)
Table 37. World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2027-2032) & (USD Million)
Table 38. World Oncogene-Targeted Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Oncogene-Targeted Drugs Market Size by Application (2021-2026) & (USD Million)
Table 40. World Oncogene-Targeted Drugs Market Size by Application (2027-2032) & (USD Million)
Table 41. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 42. Johnson & Johnson Major Business
Table 43. Johnson & Johnson Oncogene-Targeted Drugs Product and Services
Table 44. Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Johnson & Johnson Recent Developments/Updates
Table 46. Johnson & Johnson Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Oncogene-Targeted Drugs Product and Services
Table 50. Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. Pfizer Basic Information, Manufacturing Base and Competitors
Table 54. Pfizer Major Business
Table 55. Pfizer Oncogene-Targeted Drugs Product and Services
Table 56. Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Pfizer Recent Developments/Updates
Table 58. Pfizer Competitive Strengths & Weaknesses
Table 59. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca Major Business
Table 61. AstraZeneca Oncogene-Targeted Drugs Product and Services
Table 62. AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca Recent Developments/Updates
Table 64. AstraZeneca Competitive Strengths & Weaknesses
Table 65. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 66. Eli Lilly Major Business
Table 67. Eli Lilly Oncogene-Targeted Drugs Product and Services
Table 68. Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Eli Lilly Recent Developments/Updates
Table 70. Eli Lilly Competitive Strengths & Weaknesses
Table 71. Novartis Basic Information, Manufacturing Base and Competitors
Table 72. Novartis Major Business
Table 73. Novartis Oncogene-Targeted Drugs Product and Services
Table 74. Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Novartis Recent Developments/Updates
Table 76. Novartis Competitive Strengths & Weaknesses
Table 77. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 78. Bristol Myers Squibb Major Business
Table 79. Bristol Myers Squibb Oncogene-Targeted Drugs Product and Services
Table 80. Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Bristol Myers Squibb Recent Developments/Updates
Table 82. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 83. Bayer Basic Information, Manufacturing Base and Competitors
Table 84. Bayer Major Business
Table 85. Bayer Oncogene-Targeted Drugs Product and Services
Table 86. Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Bayer Recent Developments/Updates
Table 88. Bayer Competitive Strengths & Weaknesses
Table 89. Takeda Basic Information, Manufacturing Base and Competitors
Table 90. Takeda Major Business
Table 91. Takeda Oncogene-Targeted Drugs Product and Services
Table 92. Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Takeda Recent Developments/Updates
Table 94. Takeda Competitive Strengths & Weaknesses
Table 95. Amgen Basic Information, Manufacturing Base and Competitors
Table 96. Amgen Major Business
Table 97. Amgen Oncogene-Targeted Drugs Product and Services
Table 98. Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Amgen Recent Developments/Updates
Table 100. Amgen Competitive Strengths & Weaknesses
Table 101. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 102. Boehringer Ingelheim Major Business
Table 103. Boehringer Ingelheim Oncogene-Targeted Drugs Product and Services
Table 104. Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Boehringer Ingelheim Recent Developments/Updates
Table 106. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 107. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 108. Daiichi Sankyo Major Business
Table 109. Daiichi Sankyo Oncogene-Targeted Drugs Product and Services
Table 110. Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Daiichi Sankyo Recent Developments/Updates
Table 112. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 113. Hengrui Basic Information, Manufacturing Base and Competitors
Table 114. Hengrui Major Business
Table 115. Hengrui Oncogene-Targeted Drugs Product and Services
Table 116. Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Hengrui Recent Developments/Updates
Table 118. Hengrui Competitive Strengths & Weaknesses
Table 119. Hansoh Basic Information, Manufacturing Base and Competitors
Table 120. Hansoh Major Business
Table 121. Hansoh Oncogene-Targeted Drugs Product and Services
Table 122. Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Hansoh Recent Developments/Updates
Table 124. Hansoh Competitive Strengths & Weaknesses
Table 125. Betta Basic Information, Manufacturing Base and Competitors
Table 126. Betta Major Business
Table 127. Betta Oncogene-Targeted Drugs Product and Services
Table 128. Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Betta Recent Developments/Updates
Table 130. Betta Competitive Strengths & Weaknesses
Table 131. Global Key Players of Oncogene-Targeted Drugs Upstream (Raw Materials)
Table 132. Global Oncogene-Targeted Drugs Typical Customers
LIST OF FIGURES
Figure 1. Oncogene-Targeted Drugs Picture
Figure 2. World Oncogene-Targeted Drugs Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Oncogene-Targeted Drugs Total Revenue (2021-2032) & (USD Million)
Figure 4. World Oncogene-Targeted Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Oncogene-Targeted Drugs Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 13. Oncogene-Targeted Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. World Oncogene-Targeted Drugs Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. China Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 23. India Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Oncogene-Targeted Drugs by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oncogene-Targeted Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oncogene-Targeted Drugs Markets in 2025
Figure 27. United States VS China: Oncogene-Targeted Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Oncogene-Targeted Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Oncogene-Targeted Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Oncogene-Targeted Drugs Market Size Market Share by Type in 2025
Figure 31. Axitinib (Inlyta)
Figure 32. Ponatinib (Iclusig)
Figure 33. Imatinib (Gleevec)
Figure 34. Sunitinib (Sutent)
Figure 35. Pazopanib (Votrient)
Figure 36. Dabrafenib (Tafinlar)
Figure 37. Vandetanib (Caprelsa)
Figure 38. Vemurafenib (Zelboraf)
Figure 39. Vandetanib (Caprelsa)
Figure 40. World Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2032)
Figure 41. World Oncogene-Targeted Drugs Market Size by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Figure 42. World Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process in 2025
Figure 43. Chemical Synthesis Product
Figure 44. Semi-Synthetic Product
Figure 45. Recombinant Expression Product
Figure 46. Cell-Culture Derived Product
Figure 47. Enzymatic Synthesis Product
Figure 48. Oligonucleotide Solid-Phase Synthesis Product
Figure 49. Conjugation Process Product
Figure 50. Conjugation Process Product
Figure 51. World Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2021-2032)
Figure 52. World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Figure 53. World Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation in 2025
Figure 54. Bottle Presentation
Figure 55. Blister Presentation
Figure 56. Vial Presentation
Figure 57. Ampoule Presentation
Figure 58. Prefilled Syringe Presentation
Figure 59. Cartridge Presentation
Figure 60. Infusion Bag Presentation
Figure 61. Infusion Bag Presentation
Figure 62. World Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2021-2032)
Figure 63. World Oncogene-Targeted Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 64. World Oncogene-Targeted Drugs Market Size Market Share by Application in 2025
Figure 65. Clinic
Figure 66. Hospital
Figure 67. Others
Figure 68. World Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2032)
Figure 69. Oncogene-Targeted Drugs Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Oncogene-Targeted Drugs Picture
Figure 2. World Oncogene-Targeted Drugs Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Oncogene-Targeted Drugs Total Revenue (2021-2032) & (USD Million)
Figure 4. World Oncogene-Targeted Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Oncogene-Targeted Drugs Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Oncogene-Targeted Drugs Revenue (2021-2032) & (USD Million)
Figure 13. Oncogene-Targeted Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. World Oncogene-Targeted Drugs Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. China Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 23. India Oncogene-Targeted Drugs Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Oncogene-Targeted Drugs by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oncogene-Targeted Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oncogene-Targeted Drugs Markets in 2025
Figure 27. United States VS China: Oncogene-Targeted Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Oncogene-Targeted Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Oncogene-Targeted Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Oncogene-Targeted Drugs Market Size Market Share by Type in 2025
Figure 31. Axitinib (Inlyta)
Figure 32. Ponatinib (Iclusig)
Figure 33. Imatinib (Gleevec)
Figure 34. Sunitinib (Sutent)
Figure 35. Pazopanib (Votrient)
Figure 36. Dabrafenib (Tafinlar)
Figure 37. Vandetanib (Caprelsa)
Figure 38. Vemurafenib (Zelboraf)
Figure 39. Vandetanib (Caprelsa)
Figure 40. World Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2032)
Figure 41. World Oncogene-Targeted Drugs Market Size by Manufacturing Process, (USD Million), 2021 & 2025 & 2032
Figure 42. World Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process in 2025
Figure 43. Chemical Synthesis Product
Figure 44. Semi-Synthetic Product
Figure 45. Recombinant Expression Product
Figure 46. Cell-Culture Derived Product
Figure 47. Enzymatic Synthesis Product
Figure 48. Oligonucleotide Solid-Phase Synthesis Product
Figure 49. Conjugation Process Product
Figure 50. Conjugation Process Product
Figure 51. World Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2021-2032)
Figure 52. World Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation, (USD Million), 2021 & 2025 & 2032
Figure 53. World Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation in 2025
Figure 54. Bottle Presentation
Figure 55. Blister Presentation
Figure 56. Vial Presentation
Figure 57. Ampoule Presentation
Figure 58. Prefilled Syringe Presentation
Figure 59. Cartridge Presentation
Figure 60. Infusion Bag Presentation
Figure 61. Infusion Bag Presentation
Figure 62. World Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2021-2032)
Figure 63. World Oncogene-Targeted Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 64. World Oncogene-Targeted Drugs Market Size Market Share by Application in 2025
Figure 65. Clinic
Figure 66. Hospital
Figure 67. Others
Figure 68. World Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2032)
Figure 69. Oncogene-Targeted Drugs Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
